Enhancing the QUAlity and Transparency Of health Research
Use your browser's Back button to return to your search results
Reporting guideline provided for? (i.e. exactly what the authors state in the paper) |
Systematic reviews with a focus on health equity. PRISMA-Equity checklist Word / PDF |
Full bibliographic reference | Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10): e1001333. |
Language | English |
PubMed ID | 23222917 |
Explanation and elaboration papers | Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration. The explanation and elaboration paper for this guideline was published simultaneously in 2 journals. You can read the explanation and elaboration paper in either of these journals using the links below. Int J Equity Health. 2015;14(1):92. PMID: 26450828 J Clin Epidemiol. 2015. PMID: 26348799 |
Availability in additional languages | The full-text of the PRISMA-Equity 2012 guideline is available in Spanish. Visit our translations page to find out what other reporting guidelines are available in languages other than English: reporting guideline translations |
Relevant more generic / specialised reporting guidelines (i.e. main generic guideline or extension to a generic guideline) |
Generic PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583. PMID: 33780438 BMJ 2021;372:n71. PMID: 33782057 Int J Surg. 2021:105906. PMID: 33789826 J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819 Syst Rev. 2021;10(1):89. PMID: 33781348 Specialised PRISMA for Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper. PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246 PRISMA-IPD: Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. PMID: 25919529 PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634 PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668 PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: 28720516 PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: 29362800 PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033 PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367 PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791 PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365 PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229 PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev. 2021;10(1):39. PMID: 33499930 J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662 PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024. J Clin Epidemiol. 2024:111422. PMID: 38849061 Qual Life Res. 2024. PMID: 38980635 Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063 J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535 |
Reporting guideline website URL | http://www.prisma-statement.org/Extensions/Equity |
Reporting guideline acronym | PRISMA-Equity 2012 or PRISMA-E 2012 |
Study design | Systematic reviews/Meta-analyses/Reviews/HTA/Overviews |
Applies to the whole report or to individual sections of the report? | Whole report |
Additional information | Guidance for developing protocols for systematic reviews and meta-analyses is provided in the PRISMA-P Statement. For further details please visit: PRISMA-P Statement |
Record last updated on | July 16, 2024 |